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Abstract
Background and Aims The standard treatment regimen
for chronic HCV genotype 3 (HCV-G3) hepatitis consists
of PEGylated interferon-a (IFN-a) and ribavirin at varying
doses ranging from 400 to 1,200 mg and results in response
rates of 80%. However, this therapy has substantial side-
effects including anemia, is teratogenic, and costly. To
reduce the side-effects of therapy, the role of monotherapy
consisting of only IFN-a was investigated.
Methods A retrospective analysis of individual therapy
courses of HCV-G3-infected patients who were treated
with IFN-a2a monotherapy or a combination therapy with
attention to the treatment outcome and the presence of
IL28B rs12979860 and IL28B rs8099917 single-nucleotide
polymorphism genotypes was performed. Conventional
prognostic features in each case were assessed as well.
Results In the study, 15/30 (50%) of patients treated with
IFN-a2a monotherapy and 32/36 (89%) treated with com-
bination therapy achieved a sustained virological response
(SVR). In addition, 7/11 (64%) of those treated initially
with monotherapy and subsequently with combination
therapy achieved an SVR. An ‘‘ultra-rapid’’ virological
response occurring within 2 weeks of initiation of therapy
(p = 0.005), young age (\40; p\0.001) and low initial
c-GT/ALT-ratio (p = 0.03) were associated with a SVR to
IFN-a2a monotherapy. An SVR in those treated with
combination therapy was found to be associated with a
rapid virological response (RVR) (p = 0.03). The absence
of histologic steatosis was associated with SVR in all
patient groups (p = 0.01). Therapy duration (24 vs.
48 weeks) did not affect the SVR in either group. As
expected, combination therapy resulted in more hemato-
logical side-effects than did monotherapy.
Conclusions An‘‘ultra-rapid’’virologicalresponse,young
age, low initial c-GT/ALT-ratio and absence of steatosis
wereeachassociatedwithanSVRinthosereceivingIFN-a2a
monotherapy. Therefore, monotherapy in these patients
should still be discussed independently of the existence of
the IL28B polymorphisms.
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Introduction
In the 1990s, chronic hepatitis C virus (HCV) infection
began to be treated with an interferon alpha (IFN-a)
monotherapy. Dependent on HCV genotype, viral load,
IFN-a dose, and treatment duration, sustained virological
response (SVR) rates of up to 55% could be achieved in
patients with HCV non-1 genotypes [1]. Patients with HCV
genotype 3 (HCV-G3) infection had SVR rates of 38% [2]
to 67% [3] dependent of IFN-a dose. Studies that compared
conventional IFN-a monotherapy to PEGylated interferon
alpha (PEG-IFN-a) monotherapy achieved SVR rates of
28–46 and 38–68%, respectively [4, 5]. Furthermore,
studies that compared the efﬁcacy of the combination
therapy of PEG-IFN-a or IFN-a and ribavirin (RBV) to
monotherapy used IFN-a dose of 3 million units three
times per week. SVR rates of patients with HCV-G3 were
thus 21–32% [6, 7] for IFN-a and 38–45% for PEG-IFN-a
[5, 8]. In subpopulations of HCV-G3 patients with low
baseline viral load, 58% of those who were treated with
PEG-IFN-a achieved SVR [8]. However, currently the
standard treatment for patients with HCV-G3 is a combi-
nation therapy of PEG-IFN-a/RBV for 24 weeks attaining
SVR rates of up to 80% [9]. Current recommendations for
treatment of HCV genotype 2 or 3-infected patients are
based on the result of a trial that compared 24–48 weeks of
treatment with PEG-IFN-a/RBV [10]. Patients with HCV-
G3 were treated with a schedule (RBV: 800 mg/day or
1,000/1,200 mg/day) similar to that of HCV genotype 1.
A subsequent study of chronic HCV genotype 2 or
3-infected patients with PEG-IFN-a and 800 mg/day RBV
but reduced duration [11] showed that SVR rates in a
subpopulation of patients with low virus load and rapid
virological response (RVR) were similar. Dalgard et al.
[12] treated patients with chronic HCV-infected genotype 2
or 3 for 14 weeks with PEG-IFN-a and RBV 800 to
1,400 mg/day. SVR rates after 14 weeks of treatment were
achieved more frequently among subtype 3a patients with
low viral load and absence of bridging ﬁbrosis/cirrhosis. A
further study compared reduced doses of RBV (400 and
800 mg/day) for 24 weeks with equivalent outcomes in
patients infected with HCV-G3 [13].
Interestingly, comparison of combination therapy with
IFN-a monotherapy in patients with early virological
response in HCV genotype 2 or 3 showed no signiﬁcant
differences with regard to the outcome [14]. Furthermore,
two published studies showed acceptable SVR rates for
patients with HCV genotype 2 or 3 after treatment with
IFN-a monotherapy [15, 16]. Patients with virological
response between 7 days and 2 weeks have the greatest
chance of achieving an SVR.
Since the combination therapy with RBV increases the
rate of side-effects, the discontinuation rate is more fre-
quent [17]. The combination therapy is associated with a
range of treatment-limiting serious adverse events in 4–9%
in patients with HCV genotype 2 or 3 [11]. Patients’
hemoglobin concentration decreases under combination
therapy with RBV signiﬁcantly [18]. RBV-related anemia
is an increased risk in patients with impaired renal dys-
function [19]. Because of the teratogenicity and the accu-
mulation of RBV, contraception is strictly essential during
and 6 months after therapy.
For these reasons, the current strategy for the treatment
of chronic HCV infection is to individualize the treatment
duration guided to HCV genotype and on-treatment viral
response. Since the efﬁcacy of therapy signiﬁcantly
depends on the virus genotype and on the host’s clinical,
biochemical, and genetic background [20, 21], new thera-
peutic regimens have to be considered. Host genetic pre-
dictors for a successful therapy have been identiﬁed
upstream of the interleukin 28B (IL28B)/IFN-k3 gene.
One single-nucleotide polymorphism (SNP), IL28B
rs12979860, was independently and highly associated with
SVR in patients with HCV genotype 1 [22]. In HCV
genotype 2b patients who were treated with combination
therapy, IL28B SNP rs8099917 was an independent factor
for SVR, and, conversely, patients with HCV genotype 2a
treated with IFN-a monotherapy, IL28B SNP rs8099917
was also an independent factor for SVR [23]. In patients
with HCV-G3 treated with the combination therapy both
IL28B-SNPs (rs12979860 and rs8099917) were not asso-
ciated with SVR but with early virological response [24].
The impact of these two SNPs regarding combination
therapy or IFN-a monotherapy has not been reported. Two
subgroups of patients with HCV-G3 at our center who were
treated either with combination therapy or IFN-a2a mono-
therapy provided the opportunity to assess the impact of the
SNP rs12979860 and rs8099917 for SVR in addition to
other clinical prognostic markers.
Materials and Methods
Patients
Sixty-six patients with chronic hepatitis C genotype 3 who
were HCV-RNA-positive for more than 6 months were
treated between 1994 and 2010. Thirty were treated with
IFN-a2a monotherapy and 36 were treated with the stan-
dard combination therapy consisting of IFN-a and RBV.
Eleven of 30 (50%) patients initially treated with
IFN-a2a monotherapy did not achieve an SVR and were
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chronicity was deﬁned histopathologically by using estab-
lished criteria [25]. In the patients who refused liver
biopsy, chronicity was documented by longitudinal obser-
vation and the presence of advanced clinical liver disease.
Inclusion criteria consisted of the following: (1) chronic
hepatitis C by clinical criteria and/or histopathology, (2)
HCV-antibody and HCV-RNA positivity, (3) genotype 3
infection. The exclusion criteria were decompensated liver
disease, poorly controlled diabetes, clinically active auto-
immune disorders, an elevated serum alpha-fetoprotein
concentration, active alcohol or injection drug abuse, a
history of major psychiatric disease, anemia (hemoglo-
bin\120 g/l), a reduced white blood cell (WBC) count
(\3,000/ll) or thrombocytopenia (\50,000/ll), and preg-
nancy. In addition, the presence of active hepatitis A virus,
human immunodeﬁciency virus, hepatitis B virus, cyto-
megalovirus, or an Epstein–Barr virus infection utilizing
upon conventional laboratory diagnostic tests resulted in
exclusion.
The study was approved by the local ethics committee
and conformed to the ethical guidelines of the 1975 Dec-
laration of Helsinki. Informed written consent was obtained
from all subjects.
Laboratory Procedures
Detection of Serum HCV-Speciﬁc RNA by RT-PCR
RNA was extracted from serum samples (140 ll) using the
QIAamp Viral RNA Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. One-ﬁfth of the
extracted material was subjected to a nested RT-PCR
procedure as described [26].
Determination of HCV Genotypes
In HCV RNA-positive sera, virus genotyping was per-
formed using the Innolipa HCV II line probe assay (In-
nogenetics, Ghent, Belgium).
Isolation of Genomic DNA
Genomic DNA was puriﬁed from peripheral blood mono-
nuclear cells (PBMCs) through the use of the QIAamp
DNA Mini Kit following the manufacturer’s blood and
body ﬂuid spin protocol (Qiagen). The concentration and
the purity of the DNA isolated from PBMCs were deter-
mined photometrically by reading the absorbance levels at
260 and 280 nm. The integrity of genomic DNA was
ascertained through electrophoresis using a 0.6% agarose
gel.
Single-Nucleotide Polymorphism Genotyping
by 50-Nuclease Assay
Genomic DNA (5 ng derived from PBMCs or an aliquot
corresponding to 16.7 ll serum) was ampliﬁed in a total
volume of 20 ll by real-time PCR using the TaqMan
Universal Master Mix (Applied Biosystems, Darmstadt,
Germany) and 36 lmol/l at each primer in each case
[IL28B rs rs12979860: forward, 50-GCCTGTCGTGTAC
TGAACCA-30; reverse 50-GCGCGGAGTGCAATTCA
AC-30]. Allelic discrimination was achieved by adding
8 lmol/l differentially ﬂuorescent dye-labeled allele-spe-
ciﬁc minor groove binder (MGB) probes (IL28B: VIC,
50-TGGTTCGCGCCTTC-30; FAM, 50-CTGGTTCACGCC
TTC-30). IL28B rs8099917 was genotyped using a prede-
signed TaqMan SNP Genotyping Assay (Applied Biosys-
tems; assay ID C__11710096_10). Reactions and analyses
were carried out in the sequence detection system ABI
prism step one plus (Applied Biosystems) according to the
manufacturer’s instructions.
Treatment Regimens
IFN-a2a 3-6 Million Units (MU) (Roferon-A, F. Hoff-
mann-La Roche, Basel, Switzerland) was administered
either daily or three times a week in those receiving
monotherapy. PEG-IFN-a was administered once a week to
those receiving combination therapy. Treatment was for 24
or 48 weeks, as treatment follow-up period of 48 weeks
after the end of treatment (EOT) was utilized to deﬁne an
SVR. All patients with an SVR were undetectable for
HCV-RNA in serum 24 weeks and 48 weeks after the EOT.
An ‘‘ultra-rapid’’ virological response was deﬁned as serum
HCV-RNA negativity at week 2. RVR was deﬁned as
undetectable serum HCV-RNA at week 4 of therapy.
Monitoring Procedures
Patients were assessed in an outpatient setting at weeks 2,
4, 6, 8, and every 4th week thereafter during treatment.
Follow-up assessments were made at week 24 and 48 after
EOT. Clinical examinations consisting of blood cell counts
and routine biochemical tests were conducted at each clinic
visit. Laboratory values were normalized by dividing the
measurement by the upper limit of normal used as a con-
tinuous variable. HCV-RNA by RT-PCR was assessed at
time zero and at week 2, 4, 12, 24, 36, and 48 during the
48-week treatment regimen and at time zero and weeks 2,
4, 12, and 24 for patients treated for 24 weeks. During the
follow-up period, the presence of HCV-RNA in serum was
assessed at week 24 and 48 after the EOT.
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Before starting therapy, liver biopsies for histological
evaluation were taken from 51 (77%) patients. Sections
(5–10 lm) from formalin-ﬁxed and parafﬁn-embedded
blocks were stained with hematoxylin and eosin (H&E),
trichrome, and Prussian blue. Necroinﬂammatory activity
(grading: score 1–3) and structural alterations (staging:
scored 0–4) were scored separately according to Desmet
et al. [27]. Other characteristic lesions of hepatitis C, such
as the degree of steatosis (score 0–3) were reported and
graded as described previously [25].
Statistical Analyses
Continuous and categorical variables were compared
between the two groups by Wilcoxon Mann–Whitney test,
v
2 test and Fisher’s exact test. A p value less than 0.05 was
considered to be statistically signiﬁcant. Hardy–Weinberg
equilibrium calculations cited at http://ihg.gsf.de/cgi-bin/
hw/hwl.pl were used as well. All statistical analyses were
performed using the free available statistic program R cited
at http://www.r-project.org.
Results
Baseline Characteristics of the Patients
Data on 66 chronic HCV-infected patients (17 females, 49
males, mean age of 49 years, ranging from 23 to 61 years)
were evaluated retrospectively with regard to the outcome
of antiviral therapies and with regard to pretreatment serum
enzymatic activities (AST, ALT, and c-GT) and with
regard to pre- and on-treatment hematological parameters
(hemoglobin (Hb), and platelet and white blood cell
(WBC) counts). Thirty (45%) naive patients had IFN-a2a
monotherapy, 36 (55%) naive patients had deﬁnitive
combination therapy, and 11 (37%) therapy experienced
patients with initial IFN-a2a who were non-virological
responder (non-SVR) were treated with combination ther-
apy. Table 1 summarizes baseline demographic, biochem-
ical, and virological characteristics of all patients with
regard to different therapy regime. The two groups did not
differ with regard to gender, age, HCV genotype, normal-
ized AST, ALT, c-GT activities, and hematological
parameters nor IL28B genotype distributions or c-GT/ALT
ratio.
Genotyping of the two SNPs under investigation, IL28B
rs12979860 and IL28B rs8099917, revealed distributions
and minor allele frequencies (MAF) close to that given for
Caucasians in public databases (IL28B rs12979860
CC:CT:TT 33:29:4 MAF 0.280, IL28B rs8099917
TT:TG:GG 49:16:1 MAF 0.136). For the patients as a
whole, no deviation from Hardy–Weinberg equilibrium
was found (IL28B rs12979860 p = 0.29 and IL28B
rs8099917 p = 0.06).
Characteristics of Patients Treated with IFN-a2a
Monotherapy
Fifteen of 30 (50%) patients treated with IFN-a2a achieved
SVR. Factors found to be signiﬁcantly associated with
response were young age under 40 (p\0.001), ‘‘ultra-
rapid’’ virological response within 2 weeks (p = 0.005),
and low c-GT/ALT-ratio (p = 0.03). Neither gender, HCV
subtype, pre-treatment normalized AST, ALT, c-GT levels,
normalized hematological values, IL28B rs12979860
or IL28B rs8099917 genotypes nor therapy duration
(24 weeks vs. 48 weeks) were found to be related to
treatment outcome (Table 2).
Table 1 Baseline characteristics of chronic HCV-G3-infected
patients provided with an IFN-a2a mono- or combination therapy
IFN-a2a mono-
therapy (n = 30)
Combination
therapy (n = 36)
p value
Gender (female/
male)
10/20 7/29 0.32
a
Mean age
(years ± SD)
50.4 ± 9.5 47.8 ± 11.9 0.46
b
HCV subtype (3a/
3c)
22/8 26/10 0.99
a
AST-N
(mean ± SD)
1.18 ± 0.80 1.63 ± 1.25 0.07
b
ALT-N
(mean ± SD)
1.81 ± 1.27 2.46 ± 2.03 0.10
b
c-GT-N
(mean ± SD)
0.81 ± 0.63 0.86 ± 0.74 0.33
b
Hb-N
(mean ± SD)
1.21 ± 0.09 1.16 ± 0.08 0.53
b
Platelet 9 10
3/ll
(mean ± SD)
198 ± 48 215 ± 53 0.13
b
WBC 9 10
3/ll
(mean ± SD)
6.69 ± 1.64 7.15 ± 1.88 0.24
b
IL28B
rs12979860
(CC:CT:TT)
13:14:3
(43%:47%:10%)
20:15:1
(55%:42%:3%)
0.37
c
IL28B rs8099917
(TT:TG:GG)
19:10:1
(63%:33%:4%)
30:6:0
(83%:17%:0%)
0.14
c
Low c-GT/ALT-
ratio
18 (60%) 28 (78%) 0.32
a
N normalized
a Fisher’s exact test
b Wilcoxon Mann–Whitney test
c v
2 test
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Therapy
Thirty-nine of forty-seven (83%) patients with combination
therapy achieved SVR. Only RVR (p = 0.03) as an on-
treatment factor was associated with SVR, while neither
gender, age, HCV subtype, pre-treatment normalized AST,
ALT, c-GT and pre-treatment, hematological values, ther-
apy duration, nor IL28B rs12979860 or IL28B rs8099917
genotypes were associated with antiviral treatment out-
come (Table 3). Evaluated hematological values until 12
weeks differed signiﬁcantly with regard to response.
Patients who developed anemia and thrombocytopenia
within 8 weeks and leucopenia within 12 weeks during
combination therapy showed association to SVR (data not
shown). Patients under combination therapy also showed
the development of pancytopenia within 12 weeks under
the combination therapy.
Comparison of Hematological Values with Regard
to Mono- or Combination Therapy
Further examinations were conducted to evaluate pre- and
on-treatment hematological factors in terms of therapy
regime. Hb levels of patients with monotherapy decreased
but development of anemia could not be observed. Both
therapy regimes caused thrombocytopenia and leucopenia
but the combination therapy had a more pronounced effect.
In comparison to monotherapy patients, under a combina-
tion therapy, pancytopenia developed (Table 4), but only
decrease of Hb-N within 4 weeks and development of
anemia at week 8 and 12 was signiﬁcantly associated with
combination therapy.
Evaluation of Histological Examinations for Outcome
Prior to treatment, 51 patients underwent histological
examinations. These results were evaluated with regard to
outcome independently of therapy regime. Only absence of
steatosis (p = 0.01) was found to be associated with SVR,
while neither the degree of hepatitis activity nor ﬁbrosis
stage were observed to be related to response (Table 5).
Discussion
In this retrospective uncontrolled and monocentric study,
the experience of 66 consecutive patients infected with
genotype 3 HCV who received either IFN-a2a monotherapy
Table 2 Comparison of pre-
and on-treatment characteristics
of chronic HCV-G3-infected
patients treated with an IFN-a2a
monotherapy with regard to
therapy outcome
N normalized
a Fisher’s exact test
b Wilcoxon Mann–Whitney test
c v
2 test
?SVR (n = 15) -SVR (n = 15) p value
Gender (female/male) 6/9 4/11 0.69
a
Mean age (years ± SD) 38.4 ± 7.8 50.1 ± 9.5 \0.001
b
HCV subtype (3a/3c) 11/4 11/4 1
a
AST-N (mean ± SD) 0.97 ± 0.74 0.90 ± 0.41 0.52
b
ALT-N (mean ± SD) 1.69 ± 1.66 1.33 ± 0.78 0.79
b
c-GT-N (mean ± SD) 0.74 ± 0.82 0.58 ± 0.44 0.84
b
Hb-N (mean ± SD) 1.22 ± 0.11 1.19 ± 0.07 0.93
b
Platelet 9 10
3/ll (mean ± SD) 192 ± 45 203 ± 47 0.60
b
WBC 9 10
3/ll (mean ± SD) 6.12 ± 1.67 6.91 ± 1.42 0.08
b
IL28B rs12979860 (CC:CT:TT) 6:9:0 (40%:60%:0%) 7:5:3 (47%:33%:20%) 0.12
c
IL28B rs8099917 (TT:TG:GG) 11:4:0 (73%:27%:0%) 10:4:1 (67%:27%:6%) 0.48
c
HCV neg. 2 week (ultra-rapid
virological response)
12 (80%) 4 (27%) 0.005
a
Low c-GT/ALT 12 (80%) 6 (40%) 0.03
a
Therapy duration/regime (weeks) 0.5
a
24 6 (40%) 5 (33%)
48 9 (60%) 10 (67%)
IFN-a2a (dose)
24 weeks (9–21 Mio/week) 0 4 (27%)
24 weeks (18–42 Mio/week) 6 (40%) 1 (6%)
48 weeks (9–42 Mio/week) 8 (54%) 10 (67%)
48 weeks (PEG-IFN-a 180 lg/week) 1 (6%) 0
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and RBV (n = 36) or both (n = 11), is reported. The
patients were treated for either 24 or 48 weeks. Six months
after the EOT, 54/67 patients (82%) had achieved a SVR;
15/30 (50%) responded to IFN-a2a monotherapy while
32/36 (89%) responded to combination therapy with an
additional 11 of having initially received monotherapy
achieved a SVR with combination therapy. Factors asso-
ciated with an SVR whether assessed pre- or on-treatment
with IFN-a2a monotherapy were age (\40), the develop-
ment of ‘‘ultra-rapid’’ virological response occurring within
2 weeks of the initiation of therapy and a low initial c-GT/
ALT-ratio. Factors associated with an SVR with the com-
bination therapy were an RVR, decreases of Hb, WBC
count, platelet count, and the degree of steatosis. The nadir
Hb value on combination therapy was signiﬁcantly lower
than that of IFN-a2a monotherapy group.
In chronically HCV-infected patients, SVR rates range
up to 80% among patients infected with genotype 2 or 3
[9]. The therapeutic options for individuals with a genotype
Table 3 Comparison of pre- and on-treatment characteristics of
chronic HCV-G3-infected patients treated with a combination therapy
with regard to therapy outcome
?SVR (n = 39) -SVR (n = 8) p value
Gender (female/
male)
9/30 2/6 0.73
a
Mean age
(years ± SD)
49.3 ± 12.1 47.6 ± 7.5 0.15
b
HCV subtype (3a/
3c)
29/10 6/2 0.67
a
AST-N
(mean ± SD)
1.43 ± 1.19 1.64 ± 1.04 0.1
b
ALT-N
(mean ± SD)
2.35 ± 1.99 1.41 ± 0.96 0.23
b
c-GT-N
(mean ± SD)
0.74 ± 0.59 0.91 ± 1.08 0.35
b
Hb-N
(mean ± SD)
1.18 ± 0.08 1.17 ± 0.09 0.25
b
Platelet 9 10
3/ll
(mean ± SD)
214 ± 56 205 ± 38 0.42
b
WBC 9 10
3/ll
(mean ± SD)
7.15 ± 1.85 6.81 ± 1.75 0.31
b
IL28B rs12979860
(CC:CT:TT)
20:16:3
(51%:41%:8%)
4:3:1
(50%:38%:12%)
0.9
c
IL28B rs8099917
(TT:TG:GG)
29:9:1
(74%:23%:3%)
7:1:0
(88%:12%:0%)
0.48
c
RVR 31 (80%) 3 (38%) 0.03
a
Low c-GT/ALT-
ratio
26 (74%) 4 (50%) 0.21
a
Therapy duration/
regime (weeks)
0.66
a
24 33 (85%) 7 (88%)
48 6 (15%) 1 (12%)
N normalized
a Fisher’s exact test
b Wilcoxon Mann–Whitney test
c v
2 test
Table 4 Comparison of hematological side-effects of IFN-a2a
monotherapy and combination therapy
IFN-a2a mono-
therapy (n = 30)
Combination
therapy (n = 36)
p value
Hb-N (mean ± SD)
Pre-treatment 1.21 (±0.09) 1.16 (±0.08) 0.53
4 weeks 1.12 (±0.11) 1.02 (±0.11) 0.04
8 weeks 1.07 (±0.11) 0.95 (±0.12) 0.005
12 weeks 1.03 (±0.11) 0.91 (±0.11) 0.004
Platelet 9 10
3/ll (mean ± SD)
Pre-treatment 198 (±48) 216 (±53) 0.12
4 weeks 157 (±45) 157 (±55) 0.96
8 weeks 146 (±43) 130 (±46) 0.09
12 weeks 142 (±45) 125 (±50) 0.08
WBC 9 10
3/ll (mean ± SD)
Pre-treatment 6.69 (±1.64) 7.22 (±1.88) 0.24
4 weeks 4.23 (±1.73) 4.43 (±1.85) 0.86
8 weeks 4.00 (±1.52) 4.09 (±3.78) 0.24
12 weeks 3.91 (±1.53) 3.20 (±1.16) 0.06
Wilcoxon Mann–Whitney test was applied; N normalized
Table 5 Histological features of chronic HCV-G3-infected with
regard to outcome n (%)
?SVR (n = 40) -SVR (n = 11) p value
Hepatitis ns
Mild 32 (80%) 8 (73%)
Moderate 7 (18%) 2 (18%)
Severe 1 (2%) 1(9%)
Fibrosis ns
Absent 25 (63%) 5 (46%)
Mild 11 (27%) 3 (27%)
Moderate 0 0
Marked 0 2 (18%)
Cirrhosis 4 (10%) 1 (9%)
Steatosis 0.01
Absent 20 (50%) 1 (9%)
Mild 12 (30%) 6 (55%)
Moderate 7 (18%) 4 (36%)
Marked 1 (2%) 0
v
2 test was applied to compare SVR versus non-SVR with regard to
hepatitis (mild vs. moderate or severe), to ﬁbrosis (absent vs. mild,
moderate, marked or cirrhosis), and to steatosis (absent vs. mild,
moderate or marked)
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1233 infection are expanding. Recently, several studies have
proposed new strategies for treatment of these patients.
These include shortened duration of therapy [28, 29], a
reduced dose of RBV and duration of therapy [30], and
IFN-a2a monotherapy [16, 31]. These options for individ-
uals infected with genotype 3 are of great interest because
combination therapy has many side-effects, are teratogenic,
and costly. Moreover, many individuals with a chronic
HCV infection are of childbearing age and some have renal
disease that makes the use of RBV difﬁcult, if not impos-
sible. As a result, individualized treatment options need to
be considered and should be based upon recognized pre-
dictive factors for a SVR.
In recent years, many different factors predictive for a
successful therapeutic outcome have been described. In
addition to the HCV genotype [10], host-speciﬁc clinical,
laboratory, and genetic factors [22, 26, 32–34] have been
recognized. Pre-treatment laboratory factors such as c-GT/
ALT-ratio [26, 34], AST to platelet ratio index (APRI) [24,
35], or clinical and histological factors [36] should also be
considered in making a therapeutic decision.
In 2009, three different genome-wide association studies
showed that various polymorphisms in the region of IL28B
on chromosome 19 are highly associated with response in
chronic HCV-genotype-1-infected patients after having
sustained treatment with PEG-IFN-a and RBV therapy [22,
37, 38]. These polymorphisms of IL28B were associated
with response in treatment-naive and non-responders of
genotype-1-infected patients. Yu et al. [39] and Sakamoto
et al. [40] investigated the role of IL28B in chronic HCV-
genotype-2-infected patients after treatment with PEG-
IFN-a and RBV. While Yu et al. [39] reported that the
IL28B polymorphism did not predict a SVR but a RVR in
HCV genotype 2 patients, Sakamoto et al. [40] reported
that patients infected with genotype 2b with the major
allele of IL28B showed increased SVR rates. Recently,
Moghaddam et al. [24] examined the predictive ability of
the IL28B polymorphism (rs12979860 and rs8099917) in
patients with chronic HCV-G3 after treatment with com-
bination therapy. They reported that these two SNPs are not
predictive for a SVR. These results could be conﬁrmed by
Scherzer et al. [41] who suggested an association between
IL28B polymorphisms and the early virological response to
the application of a PEG-IFN-a and RBV therapy, but no
effect was observed on SVR rates in HCV-G3 patients. In
this study, we examined the predictive ability of the
mentioned IL28B polymorphisms above with regard to
monotherapy, but since the sample size of both groups are
small, the statistical analysis of IL28B genetic distribution
does not have enough power to reveal a signiﬁcant out-
come. However, rather, the ﬁndings of either a ultra rapid
or RVR [24, 41] or a reduction in Hb [18] during therapy
are associated with a SVR.
One of the reasons for the low response to standard IFN-
a is its short half-life, which leads to wide ﬂuctuations in
the plasma concentration of the drug during the treatment
period. Because HCV has a high rate of turnover [42], an
intermittent increase in viral load can be observed in
patients treated with standard IFN-a on treatment-free days
[43]. Despite these disadvantages, Bjoro et al. [44] reported
that in patients with genotype 2b/3a, low viral load and
without cirrhosis the SVR rate could be increased by IFN-a
induction (6 MU IFN-a2a daily for 4 weeks) up to 61%.
Akuta et al. [45] and Yokosuka et al. [46] reported SVR
rates of 68 and 84% in selected groups of chronic HCV-
genotype-2 treated with induction IFN-a monotherapy. In
these two studies, 6-10 MU IFN-a was administered daily
for 2–4 weeks. The addition of a polyethylene glycol
molecule to interferon produces a biologically active
molecule with a longer half-life. This characteristic allows
a more convenient dosing, i.e., once a week. In case of only
applying PEG-IFN-a to patients with chronic HCV (all
genotypes) for 48 weeks, the SVR rate was approximately
twice (39%) as high as the rate of having applied standard
IFN-a to the patients [5]. The subgroup analysis of the
prospective randomized study by Fried et al. [8] showed
that all HCV-G3 patients achieved SVR rates of 45% after
PEG-IFN-a monotherapy. Another prospective randomized
study by Angelico et al. [14] showed that selected groups
of patients with HCV-genotype 2/3 had a SVR rate of 67%
through the application of PEG-IFN-a therapy. Based upon
these data, in patients infected with HCV-G3 who are
young (\40 years), have a low viral load, histologically
mild disease, and a low initial c-GT/ALT-ratio, mono-
therapy with IFN-a is effective in 50% of the individuals
treated. As mentioned above, considerable data on the use
of PEG-IFN-a for the treatment of HCV-infected patients
are available in the literature [8, 9]. In contrast, daily
dosing of IFN-a consisting of 3 MU for 24 weeks has been
reported to achieve a 66.7% SVR rate. The patients who
achieved an SVR had an initial virological response after
only 2 weeks of IFN-a2a monotherapy [16]. These data are
in accordance with the present results and suggest that the
adverse effects of RBV can be avoided in a subgroup of
patients with HCV-G3 who show an ‘‘ultra-rapid’’ viro-
logical response within 2 weeks of the start of IFN-a
treatment. Those who do not achieve an ‘‘ultra-rapid’’ vi-
rological response can have RBV added to their therapy to
enhance the likelihood of their achieving an SVR. This
approach would eliminate the potential teratogenic effects
of RBV in patients, reduce the severity of the anemia
occurring during therapy, and reduce the cost of therapy in
those receiving monotherapy who achieve an ‘‘ultra-rapid’’
virological response.
It needs to be recognized that important limitations to
the present report exist: (1) It is a retrospective study,
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123which was placed on (2) a single center, (3), which
included only a small sample size referring to each group,
and (4) with different therapy regimes within the groups.
This study contains an explorative analysis for further
suggestions of different therapy regimes for chronic HCV-
G3 patients. In order to examine the hypothesis of this
retrospective study, a prospective trail should be initiated
that should include the suggested criteria by starting PEG-
IFN-a2a monotherapy in selected patients.
In conclusion, patients, who are under 40 years, having
a low viral load and a low initial c-GT/ALT-ratio, absence
of ﬁbrosis/cirrhosis and steatosis, and who develop an on-
treatment ‘‘ultra-rapid’’ virological response can achieve an
SVR of 50%. This subgroup of patients may beneﬁt from a
treatment regimen consisting of PEG-IFN-a monotherapy.
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